倍他司汀治疗椎基底动脉供血不足的临床研究  

Clinical research of betahistine in treatment of vertebrobasilar insufficiency

作　　者：赵溶冰[1] 宋来军[2] 陈钢[1] 徐彦华[1] 崔艳玲[1] 

机构地区：[1]大庆油田总医院集团脑血管医院,大庆163113 [2]大庆油田总医院,大庆163113

出　　处：《中国当代医药》2013年第27期70-71,73,共3页China Modern Medicine

摘　　要：目的探讨倍他司汀治疗椎基底动脉供血不足的临床效果。方法选取本院2010年12月～2012年10月诊治的椎基底动脉供血不足患者82例,随机分为观察组和对照组,对照组41例患者静脉滴注丹参注射液20 ml/次,1次/d,疗程为10 d;观察组41例患者静脉滴注倍他司汀40 mg/次,溶于500 ml 0.9%氯化钠溶液中,1次/d,疗程为10 d;两组均随访6个月,治疗前后行经颅多普勒检查,分析治疗后两组患者的临床指标、临床疗效、不良反应及复发情况。结果治疗后,两组患者的椎动脉血流速度、基底动脉血流速度、大脑后动脉血流速度显著升高;观察组的椎动脉血流速度、基底动脉血流速度、大脑后动脉血流速度、总有效率明显高于对照组,眩晕消失时间明显短于对照组,椎基底动脉供血不足复发率明显低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论倍他司汀是治疗椎基底动脉供血不足的有效药物,可明显改善患者的临床症状,提高治愈率,且安全性高,复发率低。Objective To investigate the clinical effect of betahistine in treatment of vertebrobasilar insufficiency. Methods 82 patients with vertebrobasilar insufficiency in our hospital from December 2010 to October 2012 were se- lected and randomly divided into observation group and control group,41 patients in control group were treated with in- travenous injection of salvia mihiorrhiza 20 ml/time,1 time a day,the course was 10 days;41 patients in observation group were treated with intravenous injection of betahistine 40 mg/time,solyble in 500 ml 0.9%NaC1.All patients were followed up for 6 months.Transcranial doppler examination finished in two groups before and after treatment.Clinical index,clinical effect,adverse reaction,recurrence were analyzed in two groups after treatment.Results After treatment, vertebral artery blood flow velocity,basilar artery blood flow velocity,posterior cerebral artery blood flow velocity in two groups increased significantly;vertebral artery blood flow velocity,basilar artery blood flow velocity,posterior cerebral artery blood flow yelp.city,total effective rate in observation group were significantly higher than those in control group; vertigo disappeared time in observation group was significantly less than that in control group;vertebrobasilar insuffi- ciency relapse rate in observation group was significantly lower than that in control group;there was statistical differ- ence （P〈0.05）.Incidence of adverse reaction in observation group was higher than that in control group,there was no statistical difference （P〉0.05）. Conclusion Betahistine is effective drug in treatment of vertebrobasilar insufficiency, which can obviously improve clinical symptoms and cure rate and it has high security and low recurrence rate.

关 键 词：倍他司汀 椎基底动脉供血不足 丹参注射液 

分 类 号：R743.3[医药卫生—神经病学与精神病学]